

LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A method of specifically activating cytotoxic T lymphocytes in vivo in an animal having malignant cells that express a Her-2/Neu protein, the method comprising the step of immunizing an said animal with the polypeptide of SEQ ID NO:12.

Claims 2-60 (canceled)

Claim 61 (new): A method of treating a patient having a tumor and in need of treatment of said tumor, wherein cells of said tumor express a Her-2/Neu protein, the method comprising the step of administering a polypeptide having the amino acid sequence VMAGVGSPYV (SEQ ID NO:12) to the patient.

Claim 62 (new): The method of claim 61, wherein said polypeptide is incorporated into a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

Claim 63 (new): The method of claim 61, wherein said polypeptide is linked to a carrier.

Claim 64 (new): The method of claim 61, wherein said polypeptide is administered to said patient as a homopolymer.

Claim 65 (new): The method of claim 61, further comprising the step of administering a second component to said patient, wherein said second component primes cytotoxic T lymphocytes (CTLs) for activation.

Claim 66 (new): The method of claim 65, wherein the second component comprises tripalmitoyl-S-glycercylcysteinyl-seryl-serine (P3CSS).

Claim 67 (new): The method of claim 61, further comprising the step of administering a second polypeptide to said animal.

Claim 68 (new): The method of claim 67, wherein the second polypeptide comprises TPPAYRPPNAPIL (SEQ ID NO:9).

Claim 69 (new): The method of claim 1, wherein said polypeptide is incorporated into a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

Claim 70 (new): The method of claim 1, wherein said polypeptide is linked to a carrier.

Claim 71 (new): The method of claim 1, wherein said polypeptide is administered to said animal as a homopolymer.

Claim 72 (new): The method of claim 1, wherein said immunizing step further comprises administering a second component to said animal, wherein said second component primes said CTLs for activation.

Claim 73 (new): The method of claim 72, wherein said second component comprises tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P3CSS).

Claim 74 (new): The method of claim 1, wherein the immunizing step further comprises administering a second polypeptide to said animal.

Claim 75 (new): The method of claim 74, wherein the second polypeptide comprises TPPAYRPPNAPIL (SEQ ID NO:9).